Argoubi Ramzi, Reese Emily S, Furegato Martina, Medina Patricia, Bobiak Sarah
Cerner Enviza, Kansas City, MO 64117, USA.
EMD Serono Research & Development Institute, Inc, Billerica, MA 01821, USA, an affiliate of Merck KGaA.
J Comp Eff Res. 2023 May 31;12(6):e220201. doi: 10.57264/cer-2022-0201.
Biliary tract cancers are aggressive, with poor prognosis. This study describes clinical characteristics, treatment patterns and healthcare resource utilization in patients with metastatic biliary tract cancer in Japan. This cohort-based study collected data from the Japan Medical Data Center claims database (2014-2018). A total of 325 patients were included; 65.2% were male and the mean age was 59.2 years. A 47.6% had an Elixhauser Comorbidity Index score ≥5. Most frequent regimens were gemcitabine + cisplatin (52.9%) for first-line therapy and tegafur + gimeracil + oteracil for second-line therapy (48.6%) and third-line therapy (27.2%). Approximately 77% of patients had ≥1 hospital admission, with a median length of 57 days. This study provides insights on the characteristics and burden of metastatic biliary tract cancer in Japan, highlighting high disease burden in a younger population.
胆道癌具有侵袭性，预后较差。本研究描述了日本转移性胆道癌患者的临床特征、治疗模式和医疗资源利用情况。这项基于队列的研究从日本医疗数据中心的理赔数据库（2014 - 2018年）收集数据。共纳入325例患者；65.2%为男性，平均年龄为59.2岁。47.6%的患者埃利克斯豪泽合并症指数评分≥5。一线治疗最常用的方案是吉西他滨 + 顺铂（52.9%），二线治疗（48.6%）和三线治疗（27.2%）最常用的方案是替吉奥。约77%的患者至少有1次住院，中位住院时长为57天。本研究提供了关于日本转移性胆道癌特征和负担的见解，突出了年轻人群中较高的疾病负担。
